Monique B. Nilsson

Aug 20, 2024 | digitalcommons.library.tmc.edu | Sonia Patel |Monique B. Nilsson |Xiuning Le |Tina Cascone

Home > UTHealth > GSBS > Journal Articles > 412 Clinical Cancer Reserach Humans, Vascular Endothelial Growth Factor A, Neovascularization, Pathologic, Angiogenesis Inhibitors, Neoplasms, Signal Transduction, Tumor Microenvironment DOWNLOADS Included in Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons COinS...

Aug 20, 2024 | digitalcommons.library.tmc.edu | Sonia Patel |Monique B. Nilsson |Xiuning Le |Hai T. Tran

Purpose: Patients with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations are initially responsive to tyrosine kinase inhibitors (TKI). However, therapeutic resistance eventually emerges, often via secondary EGFR mutations or EGFR-independent mechanisms such as epithelial-to-mesenchymal transition. Treatment options after EGFR-TKI resistance are limited as anti-PD-1/PD-L1 inhibitors typically display minimal benefit.